

Date of Deposit: July 18, 2002



Please type a plus sign (+) in this box



PTO/SB (12-97)

Approved for use through 9/30/00. OMB 0651-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)	Application Number	09/992,840
	Filing Date	11/06/01
	First Named Inventor	Jeffers
	Group Art Unit	Not Yet Assigned 1647
	Examiner Name	Not Yet Assigned J. Seharaseyon
	Attorney Docket Number	15966-557A

U.S. PATENT DOCUMENTS							
Exam Initials	Cite No.	U.S. Patent Document No.	Issue Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date If Appropriate

FOREIGN PATENT DOCUMENTS							
Exam Initials	Cite No.	Foreign Patent Document Office Number	Name of Patentee(s) or Applicant(s)		Date of Publication	Translation Yes No	
JS	B1	JP 5301893	Takeda Chem Ind. Ltd. English Abstract		11/16/1993		xxx

OTHER PRIOR ART - NON-PATENT LITERATURE DOCUMENTS		
Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.
JS	C1	Altschul, et al. (1990). "Basic local alignment search tool." <i>J Mol Biol</i> 215(3): 403-10.
	C2	Basilico and Moscatelli (1992). "The FGF family of growth factors and oncogenes." <i>Adv Cancer Res</i> 59: 115-65.
	C3	Danilenko (1999). "Preclinical and early clinical development of keratinocyte growth factor, an epithelial-specific tissue growth factor." <i>Toxicol Pathol</i> 27(1): 64-71.
	C4	Gasparini (1999). "The rationale and future potential of angiogenesis inhibitors in neoplasia." <i>Drugs</i> 58(1): 17-38.
	C5	GenBank Accession Number: A58788 (06-MAR-1998).
	C6	GenBank Accession Number: AA232729 (27-NOV-1996).
	C7	GenBank Accession Number: AA236522 (27-NOV-1996).
	C8	GenBank Accession Number: AAF00049 (22-JUN-2000).
	C9	GenBank Accession Number: AAF80597 (27-AUG-2001).
	C10	GenBank Accession Number: AB012615 (08-SEP-1999).
	C11	GenBank Accession Number: AB020858 (21-MAY-1999).
	C12	GenBank Accession Number: AF091434 (22-JUN-2000).
	C13	GenBank Accession Number: AJ272876 (18-NOV-1998).
	C14	GenBank Accession Number: AJ272878 (18-NOV-1998).
	C15	GenBank Accession Number: BAB03265 (26-JUL-2000).
	C16	GenBank Accession Number: E05822 (29-SEP-1997).
	C17	GenBank Accession Number: P36364 (01-NOV-1997).
	C18	GenBank Accession Number: P54130 (16-OCT-2001).
	C19	GenBank Accession Number: P98070 (16-OCT-2001).



OTHER PRIOR ART: PATENT LITERATURE DOCUMENTS		
Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.
JS	C20	GenBank Accession Number: S82023 (05-MAY-2002).
	C21	Gerwins, et al. (2000). "Function of fibroblast growth factors and vascular endothelial growth factors and their receptors in angiogenesis." <i>Crit Rev Oncol/Hematol</i> 34(3): 185-94.
	C22	Grisham (1994). "Oxidants and free radicals in inflammatory bowel disease." <i>Lancet</i> 344(8926): 859-61.
	C23	Klint and Claesson-Welsh (1999) "Signal transduction by fibroblast growth factor receptors" <i>Front. Biosci.</i> 4: d165-177.
	C24	Koga, et al. (1999). "Characterization of a novel member of the FGF family, XFGF-20, in <i>Xenopus laevis</i> ." <i>Biochem Biophys Res Commun</i> 261(3): 756-65.
	C25	La Rocca, et al. (1990). "Suramin: prototype of a new generation of antitumor compounds." <i>Cancer Cells</i> 2(4): 106-15.
	C26	Li, et al. (1997). "Activation of FGF receptors by mutations in the transmembrane domain." <i>Oncogene</i> 14(12): 1397-406.
	C27	Lichtiger, et al. (1994). "Cyclosporine in severe ulcerative colitis refractory to steroid therapy." <i>N Engl J Med</i> 330(26): 1841-5.
	C28	Lorenzi, et al. (1996). "FRAG1, a gene that potently activates fibroblast growth factor receptor by C-terminal fusion through chromosomal rearrangement." <i>Proc Natl Acad Sci U S A</i> 93(17): 8956-61.
	C29	Matsumoto-Yoshitomi, et al. (1997). "Autocrine transformation by fibroblast growth factor 9 (FGF-9) and its possible participation in human oncogenesis." <i>Int J Cancer</i> 71(3): 442-50.
	C30	Miyakawa, et al. (1999). "A hydrophobic region locating at the center of fibroblast growth factor-9 is crucial for its secretion." <i>J Biol Chem</i> 274(41): 29352-7.
	C31	Miyake, et al. (1998). "Structure and expression of a novel member, FGF-16, on the fibroblast growth factor family." <i>Biochem Biophys Res Commun</i> 243(1): 148-52.
	C32	Miyamoto, et al. (1993). "Molecular cloning of a novel cytokine cDNA encoding the ninth member of the fibroblast growth factor family, which has a unique secretion property." <i>Mol Cell Biol</i> 13(7): 4251-9.
	C33	Mount (1996). "AT-AC introns: an ATtACK on dogma." <i>Science</i> 271(5256): 1690-2.
	C34	Munkholm, et al. (1994). "Frequency of glucocorticoid resistance and dependency in Crohn's disease." <i>Gut</i> 35(3): 360-2.
	C35	Nakai and Kanehisa (1992). "A knowledge base for predicting protein localization sites in eukaryotic cells." <i>Genomics</i> 14(4): 897-911.
	C36	Naruo, et al. (1993). "Novel secretory heparin-binding factors from human glioma cells (glia-activating factors) involved in glial cell growth. Purification and biological properties." <i>J Biol Chem</i> 268(4): 2857-64.
	C37	Pearson, et al. (1995). "Azathioprine and 6-mercaptopurine in Crohn disease. A meta-analysis." <i>Ann Intern Med</i> 123(2): 132-42.
	C38	Present, et al. (1999). "Infliximab for the treatment of fistulas in patients with Crohn's disease." <i>N Engl J Med</i> 340(18): 1398-405.
	C39	Revest, et al. (2000). "Fibroblast growth factor 9 secretion is mediated by a non-cleaved amino-terminal signal sequence." <i>J Biol Chem</i> 275(11): 8083-90.
	C40	Santos-Ocampo, et al. (1996). "Expression and biological activity of mouse fibroblast growth factor-9." <i>J Biol Chem</i> 271(3): 1726-31.
	C41	EMBL Database Accession Number: Q9QY71 (1-MAY-2000).
	C42	EMBL Database Accession Number: Q9UL22 (1-MAY-2000).
	C43	Szebenyi and Fallon (1999). "Fibroblast growth factors as multifunctional signaling factors." <i>Int Rev Cytol</i> 185: 45-106.
✓	C44	Wozney, et al. (1988). "Novel regulators of bone formation: molecular clones and activities." <i>Science</i> 242(4885): 1528-34.

Express Mail No. EV 074978332/US
Date of Deposit: July 18, 2002

Page 3 of 3

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.
JS	C45	Xu, et al. (1999). "Fibroblast growth factor receptors (FGFRs) and their roles in limb development." <i>Cell Tissue Res</i> 296(1): 33-43.
JS	C46	Yates, et al. (1997). "Molecular diagnosis of thiopurine S-methyltransferase deficiency: genetic basis for azathioprine and mercaptopurine intolerance." <i>Ann Intern Med</i> 126(8): 608-14.

* a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. _____, filed _____, and relied upon for an earlier filing date under 35 U.S.C. §120 (continuation, continuation-in-part, and divisional applications).

Examiner Signature	/Jegatheesan Seharaseyon/	Date Considered	02/20/2007
-----------------------	---------------------------	--------------------	------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered.

Include copy of this form with next communication to applicant.

TRA 1685908v1

Express Mail No.: EV 138528143 US
Date of Deposit: October 18, 2002

RECEIVED

OCT 22 2002 Page 1 of 1

TECH CENTER 1600/2900



Please type a plus sign (+) in this box



PTO/SB (12-97)

Approved for use through 9/30/00. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Modified Form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)	Application Number	09/992,840
	Filing Date	November 6, 2001
	First Named Inventor	Jeffers, et al.
	Group Art Unit	Not Yet Assigned 1647
	Examiner Name	Not Yet Assigned j. Seharaseyon
	Attorney Docket Number	15966-557A

U.S. PATENT DOCUMENTS							
Exam Initials	Cite No.	U.S. Patent Document No.	Date Filed	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date If Appropriate
JS	A1	60/161,162	10/22/99	Itoh, et al.			
JS	A2	60/124,460	03/15/99	Manning, et al.			

FOREIGN PATENT DOCUMENTS							
Exam Initials	Cite No.	Foreign Patent Document Office Number		Name of Patentee(s) or Applicant(s)	Date of Publication	Translation Yes No	
JS	B2	WO	01/72957 A2	Itoh, et al.	04/10/01		
JS	B3	WO	00/54813	Manning, et al.	21/09/00		
JS	B4	WO	01/31008 A2	Itoh, et al.	03/05/01		


OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS		
Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.
JS	C47	Pickering, et al. (1997). "Fibroblast Growth Factor-2 Potentiates Vascular Smooth Muscle Cell Migration to Platelet-Derived Growth Factor" and "Upregulation of $\alpha_2\beta_1$ Integrin and Disassembly of Actin Filaments" <i>Cir. Res.</i> 80:627-637.
JS	C48	Klein, et al. (1995). "Differential Modulation of Cell Phenotype by Different Molecular Weight Forms of Basic Fibroblast Growth Factor: Possible Intracellular Signaling by the High Molecular Weight Forms" <i>J. Cell Biol. Apr.</i> 129(1):233-43. (ABSTRACT)

* a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. _____, filed _____, and relied upon for an earlier filing date under 35 U.S.C. §120 (continuation, continuation-in-part, and divisional applications).

Examiner Signature	/Jegatheesan Seharaseyon/	Date Considered	02/20/2007
--------------------	---------------------------	-----------------	------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered.

Include copy of this form with next communication to applicant.



Express Mail No.: EV074974640US
Date of Deposit: July 17, 2003

Page 1 of 1

Modified Form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)	Application Number	09/992,840
	Filing Date	November 6, 2001
	First Named Inventor	Jeffers, et al.
	Group Art Unit	Not Yet Assigned 1647
	Examiner Name	Not Yet Assigned J. Seharaseyon
	Attorney Docket Number	15966-557A

U.S. PATENT DOCUMENTS							
Exam Initials	Cite No.	U.S. Patent Document No.	Issue Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date If Appropriate

FOREIGN PATENT DOCUMENTS							
Exam Initials	Cite No.	Foreign Patent Document Office	Number	Name of Patentee(s) or Applicant(s)	Date of Publication	Translation Yes	No
JS	B5	WO	01/07595	Curagen Corporation	02/01/01		
JS	B6	WO	01/68854	Amgen, Inc.	09/20/01		
JS	B7	WO	02/02625	Curagen Corporation	01/10/02		

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS							
Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.					
JS	C49	Bikfalvi, et al. (1997). Endocrine Reviews 18: 26-45.					
JS	C50	Invitation to Pay Additional Fees for PCT/US 02/19400, mailed April 18, 2003.					
JS	C51	Kirkoshi, et al. (2000). Biochem and Biophys Res Comm 274: 337-343.					
JS	C52	International Search Report for PCT/US 01/43846, mailed May 9, 2003.					

* A copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. _____, filed _____, and relied upon for an earlier filing date under 35 U.S.C. §120 (continuation, continuation-in-part, and divisional applications).

Examiner Signature	/Jegatheesan Seharaseyon/	Date Considered	02/20/2007
---------------------------	---------------------------	------------------------	------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered.

Include copy of this form with next communication to applicant.